Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

Antje Hoering, John Crowley, John D. Shaughnessy, Klaus Hollmig, Yazan Alsayed, Jackie Szymonifka, Sarah Waheed, Bijay Nair, Frits Van Rhee, Elias Anaissie, Bart Barlogie

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy. With median times to CR in Total Therapy (TT) trials of approximately 1 year, this approach excludes a sizeable fraction of patients dying before such a landmark. To permit inclusion of all trial participants, we investigated the prognostic implications of both onset and duration of CR as time-dependent variables. Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic parameters, both failure to achieve CR (non-CR) and, especially, loss of CR (los-CR) were independently associated with inferior survival in TT1, TT2, and TT3 protocols. In the context of gene array-defined risk, available in TT2 and TT3 subsets, both los-CR and non-CR terms were retained in the survival model as dominant adverse variables, stressing the prognostic importance of sustaining CR status, especially in high-risk disease.

Original languageEnglish (US)
Pages (from-to)1299-1305
Number of pages7
JournalBlood
Volume114
Issue number7
DOIs
StatePublished - 2009

Fingerprint

Multiple Myeloma
Survival
Set theory
Genes
Chromosome Aberrations
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Hoering, A., Crowley, J., Shaughnessy, J. D., Hollmig, K., Alsayed, Y., Szymonifka, J., ... Barlogie, B. (2009). Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood, 114(7), 1299-1305. https://doi.org/10.1182/blood-2009-03-211953

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. / Hoering, Antje; Crowley, John; Shaughnessy, John D.; Hollmig, Klaus; Alsayed, Yazan; Szymonifka, Jackie; Waheed, Sarah; Nair, Bijay; Van Rhee, Frits; Anaissie, Elias; Barlogie, Bart.

In: Blood, Vol. 114, No. 7, 2009, p. 1299-1305.

Research output: Contribution to journalArticle

Hoering, A, Crowley, J, Shaughnessy, JD, Hollmig, K, Alsayed, Y, Szymonifka, J, Waheed, S, Nair, B, Van Rhee, F, Anaissie, E & Barlogie, B 2009, 'Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols', Blood, vol. 114, no. 7, pp. 1299-1305. https://doi.org/10.1182/blood-2009-03-211953
Hoering, Antje ; Crowley, John ; Shaughnessy, John D. ; Hollmig, Klaus ; Alsayed, Yazan ; Szymonifka, Jackie ; Waheed, Sarah ; Nair, Bijay ; Van Rhee, Frits ; Anaissie, Elias ; Barlogie, Bart. / Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. In: Blood. 2009 ; Vol. 114, No. 7. pp. 1299-1305.
@article{18701047e78342f9b56ec0d9fd6fc8b7,
title = "Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols",
abstract = "Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy. With median times to CR in Total Therapy (TT) trials of approximately 1 year, this approach excludes a sizeable fraction of patients dying before such a landmark. To permit inclusion of all trial participants, we investigated the prognostic implications of both onset and duration of CR as time-dependent variables. Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic parameters, both failure to achieve CR (non-CR) and, especially, loss of CR (los-CR) were independently associated with inferior survival in TT1, TT2, and TT3 protocols. In the context of gene array-defined risk, available in TT2 and TT3 subsets, both los-CR and non-CR terms were retained in the survival model as dominant adverse variables, stressing the prognostic importance of sustaining CR status, especially in high-risk disease.",
author = "Antje Hoering and John Crowley and Shaughnessy, {John D.} and Klaus Hollmig and Yazan Alsayed and Jackie Szymonifka and Sarah Waheed and Bijay Nair and {Van Rhee}, Frits and Elias Anaissie and Bart Barlogie",
year = "2009",
doi = "10.1182/blood-2009-03-211953",
language = "English (US)",
volume = "114",
pages = "1299--1305",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

AU - Hoering, Antje

AU - Crowley, John

AU - Shaughnessy, John D.

AU - Hollmig, Klaus

AU - Alsayed, Yazan

AU - Szymonifka, Jackie

AU - Waheed, Sarah

AU - Nair, Bijay

AU - Van Rhee, Frits

AU - Anaissie, Elias

AU - Barlogie, Bart

PY - 2009

Y1 - 2009

N2 - Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy. With median times to CR in Total Therapy (TT) trials of approximately 1 year, this approach excludes a sizeable fraction of patients dying before such a landmark. To permit inclusion of all trial participants, we investigated the prognostic implications of both onset and duration of CR as time-dependent variables. Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic parameters, both failure to achieve CR (non-CR) and, especially, loss of CR (los-CR) were independently associated with inferior survival in TT1, TT2, and TT3 protocols. In the context of gene array-defined risk, available in TT2 and TT3 subsets, both los-CR and non-CR terms were retained in the survival model as dominant adverse variables, stressing the prognostic importance of sustaining CR status, especially in high-risk disease.

AB - Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy. With median times to CR in Total Therapy (TT) trials of approximately 1 year, this approach excludes a sizeable fraction of patients dying before such a landmark. To permit inclusion of all trial participants, we investigated the prognostic implications of both onset and duration of CR as time-dependent variables. Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic parameters, both failure to achieve CR (non-CR) and, especially, loss of CR (los-CR) were independently associated with inferior survival in TT1, TT2, and TT3 protocols. In the context of gene array-defined risk, available in TT2 and TT3 subsets, both los-CR and non-CR terms were retained in the survival model as dominant adverse variables, stressing the prognostic importance of sustaining CR status, especially in high-risk disease.

UR - http://www.scopus.com/inward/record.url?scp=70349320472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349320472&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-211953

DO - 10.1182/blood-2009-03-211953

M3 - Article

C2 - 19515721

AN - SCOPUS:70349320472

VL - 114

SP - 1299

EP - 1305

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -